Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00425464
Other study ID # SYNC-601-IOL
Secondary ID
Status Terminated
Phase Phase 3
First received January 19, 2007
Last updated September 16, 2013
Start date November 2005
Est. completion date April 2013

Study information

Verified date September 2013
Source Abbott Medical Optics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine if the Synchrony Dual Optic Accommodating Intraocular Lens can be used safely and effectively in post cataract extraction subjects


Recruitment information / eligibility

Status Terminated
Enrollment 410
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

1. Patients must be scheduled to undergo primary intraocular lens implantation for the correction of aphakia following extraction of a senile cataract.

2. Patients must have a cataract causing reduction in visual acuity to a level of 20/40 or worse with BAT on medium setting.

3. Patients must require Synchrony® Lens correction of 16D - 28D or, if participating in the control study, patients must require a Clariflex® (AMO®), Phacoflex® II models SI30NB (AMO®) or a SI40NB (AMO®).

4. Patients must have = 1.0 D of preoperative keratometric astigmatism.

5. Patients must have clear intraocular media other than cataract(s).

6. Patients must be age 50 or older at the time of implantation.

7. Patient must be willing and able to return for all scheduled follow-up examinations and have signed a written informed consent form.

Exclusion Criteria:

1. Patients with any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.).

2. Patients with glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP > 22 mmHg.

3. Patients with previous retinal detachment or retinal pathology including age- related macular degeneration.

4. Patients with diabetes, currently being treated systemically.

5. Patients with systemic or ocular disease that may prevent the patient from achieving uncorrected distance visual acuity of 20/32 or better post operatively.

6. Patients with congenital bilateral cataract.

7. Patients who require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents. The use of tamsulosin hydrochloride (Flomax®) is also excluded preoperatively due to floppy iris syndrome.

8. Patients with best corrected visual acuity of 20/80 or worse in the fellow eye not attributable to cataract.

9. Patients who are currently participating or have participated in an investigational study, other than this study, within the past 60 days.

10. Patients who have had previous ocular surgery in the operative eye, including refractive surgery.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Standard Monofocal Intraocular Lens
The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens. Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.
Synchrony® Dual Optic Intraocular Lens
The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens. Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.

Locations

Country Name City State
United States Wallace Eye Surgery Alexandria Louisiana
United States Chu Vision Institute Bloomington Minnesota
United States Katzen Eye Care and Laser Center Boynton Beach Florida
United States Pepose Vision Institute Chesterfield Missouri
United States The Midwest Center for Sight Des Plaines Illinois
United States Drs. Fine, Hoffman & Packer Eugene Oregon
United States NorthShore University HealthSystem Glenview Illinois
United States EyeSight Hawaii Honolulu Hawaii
United States Alkek Eye Center Houston Texas
United States Harvard Eye Associates Laguna Hills California
United States Nevada Eye Care Las Vegas Nevada
United States Long Beach Laser Center Los Alamitos California
United States Altos Eye Physicians Los Altos California
United States Davis Duehr Dean Madison Wisconsin
United States Glaucoma Consultants of Colorado Parker Colorado
United States Grutzmacher & Lewis Sacramento California
United States University of Utah Hospitals and Clinics Salt Lake City Utah
United States Northwest Eye Surgeons Seattle Washington
United States Associated Eye Care Stillwater Minnesota
United States Davidorf Eye Group West Hills California

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Optics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distance corrected near visual acuity 1 Mo, 4-6 Mo, 12 Mo, 24 Mo, & 36 Mo No
Secondary Best corrected distance visual acuity 1 Mo, 4-6 Mo, 12 Mo, 24 Mo, & 36 Mo No
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A